Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.

Neurology - 8 Sept 2026

Shir Dror, Corriveau-Lecavalier Nick, Jones David T, Ramanan Vijay K, Lachner Christian, Knopman David S, Petersen Ronald C, Josephs Keith Anthony, Day Gregory S, Graff-Radford Jonathan, Graff-Radford Neill R

Abstract excerpt

BACKGROUND AND OBJECTIVES: Clinical trials of anti-amyloid therapies (AATs) for Alzheimer disease (AD) primarily enrolled patients with mildly symptomatic, amnestic predominant presentations. The applicability of eligibility criteria to atypical AD phenotypes, including posterior cortical atrophy (PCA), logopenic variant primary progressive aphasia (lvPPA), dysexecutive AD (dAD), and corticobasal syndrome because...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Alzheimer Disease
Biomarkers
CBS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Patient Selection

Source

Open in PubMed Open full text

Identifiers

PMID: 42555876
DOI: 10.1212/WNL.0000000000218347
PMCID: PMC13445492

Genes

CBS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.PMID 42555876Read ↗

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read ↗

New horizons in the diagnosis and management of Alzheimer's Disease in older adults.Semantic proximity Read ↗

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's diseaseSemantic proximity Read ↗

Are Pre-frail and Frail Amyloid Positive Individuals Eligible to Lecanemab? A cross-sectional analysis from the Cogfrail Real-World CohortSemantic proximity Read ↗

Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collectionSemantic proximity Read ↗

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read ↗

The Alzheimer’s disease drug development landscapeSemantic proximity Read ↗

Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles.Semantic proximity Read ↗

An atypical phenotype is a risk factor for higher mortality in Alzheimer’s diseaseSemantic proximity Read ↗

Characterizing individuals fulfilling clinical criteria for LATE in a tertiary memory clinicSemantic proximity Read ↗

Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. An ethical perspective.Semantic proximity Read ↗

Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.